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Abstract
DNAmethylation is an epigenetic mark associated with regulation of transcription and ge-
nome structure. These markers have been investigated in a variety of cancer settings for
their utility in differentiating normal tissue from tumor tissue. Here, we examine the direct
correlation between DNAmethylation and patient survival. We find that changes in the DNA
methylation of key pancreatic developmental genes are strongly associated with
patient survival.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States [1].
The 5-year survival rate of 6% for patients with pancreatic ductal adenocarcinomas (PDAC) is
the lowest for any solid cancer. Early detection is considered essential in order to improve pa-
tient survival as most patients present with advanced, non-operable disease [2, 3]. Recent ad-
vances in technologies for genome-wide measurements raise hope for the identification of such
early biomarkers, as well as new therapeutic targets.
Multiple deep sequencing efforts have identified large numbers of highly heterogeneous
mutations (~63 on average) with four mutations occurring at high frequency (KRAS,
CDKN1A/P16, TP53 and SMAD4) in PDAC [4, 5] These key mutations have been shown to
mechanistically drive tumorigenesis in animal models with SMAD4 associating with poor
prognosis [6]. Gene expression analysis of primary tumors has enabled construction of multi-
gene profiles that can predict metastatic disease and shorter patient survival in independent
datasets but these have yet to be used in clinical decision making [7, 8]. By combining multiple
sets of clinical data, three molecular subtypes of PDAC that predict survival and response to
therapy in experimental models have been developed [9]. Recently, 171 genes with predictive
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biomarker potential were identified by combining mRNA expression, DNA copy number vari-
ation and miRNA levels [10].
However, to date less is known about changes in DNAmethylation across pancreatic cancer
subtypes. DNAmethylation has gained much recent interest for its role in cancer biology. Ab-
errant patterns of DNA methylation are known to be associated with carcinogenesis and to af-
fect the regulation of genome stability and gene transcription [11]. Genome-wide studies of
CpG islands have uncovered thousands of loci where differential methylation can segregate
pancreatic tumor tissue from normal tissue [12, 13]. Despite this progress, the use of changes
in DNA methylation for predicting pancreatic patient survival remains unexplored.
Here we examine the direct correlation between PDAC patient survival time and methyla-
tion of individual CpG sites obtained from reduced-representation bisulfite sequencing
(RRBS). Numerous statistically significant changes in methylation correlated directly with pa-
tient survival. We observed a strong enrichment of these sites among genes involved in cell-fate
determination in the pancreas. In contrast to sequencing efforts that identified cellular signal-
ing pathways, these results suggest that cellular identity, as dictated by the tumor’s epigenome,
may be a critical component of clinically aggressive PDAC. Finally, we have further validated
the ability of a few example sites to segregate patients based on survival times, which suggests
the possibility of developing clinical biomarkers based on more extensive methylation analysis.
Results
Clinicopathologic characteristics of samples
Table 1 provides a summary of statistics for the patients used in this work. Individual patient
data can be found in S1 Table. All patients had early-stage PDAC and received adjuvant che-
motherapy. At the time of analysis, 9 patients had recurrent disease (median Disease-Free Sur-
vival (DFS) of 15.0 months), while 9 patients had died of disease (median Disease-Specific
Survival (DSS) of 25.0 months). DFS refers to the interval between treatment or removal of the
Table 1. Clinical, histopathologic, and survival information for the 11 patients used in this study.
Factor Subcategory N (%)
Total samples 11
Age, y Median (range) 65.0 (49–81)
< 65 5 (45%)
> = 65 6 (55%)
Survival, months Median (range) 25.0 (9.3–70.2)
DFS, months Median (range) 15.0 (5.4–70.2)
Tumor cellularity Median (range) 75 (60–90)
Tumor diameter, cm Median (range) 2.2
< 2.5 6 (55%)
> = 2.5 5 (45%)
T stage 2 5 (45%)
3 3 (27%)
4 3 (28%)
Tumor differentiation Well 0 (0%)
Moderate 5 (45%)
Poor 6 (45%)
Lymph nodes Positive 8 (73%)
Negative 3 (27%)
doi:10.1371/journal.pone.0128814.t001
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tumor and recurrence of the disease, while DSS refers to the interval between original diagnosis
and patient death where cause of death was the disease. For this work we have used DSS exclu-
sively. At the time of this analysis 9 patients were deceased and 2 were still living. These clinico-
pathologic characteristics and survival outcomes are similar to other published cohorts of
PDAC.
Reduced-representation bisulfite sequencing
Mapping of all quality reads to the reference human genome (hg19) yielded ~5 million CpG
sites where a confident methylation frequency could be estimated in at least one of the 16 sam-
ples. Application of the data quality filters explained above reduced this to a final number of
251,566 methylation sites used in all subsequent analysis.
Principal Component Analysis Separates Tumor from Non-tumor
Principal component analysis (PCA) of the methylation profiles for the 16 samples was per-
formed. Fig 1 shows a projection of the samples onto the first two principal axes. Along the
Fig 1. Principal Component Analysis of methylation profiles for eleven PDAC tumor samples, three pancreatitis samples, and two normal
samples.
doi:10.1371/journal.pone.0128814.g001
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first principle component there is separation of the tumor samples. Along the second principle
axis there is a clear separation between the tumor samples and the normal and pancreatitis
samples. The first component explains 24% of variance in the methylation data while the sec-
ond component explains an additional 21%.
To gain insight into the biology underlying the separation of samples along the two principle
components, we selected the 500 largest magnitude coefficients for both positive and negative
directions along each axis. As these coefficients correspond to CpG sites, we submitted them to
the Genomic Regions Enrichment of Annotations Tool (GREAT) server for annotation [14].
For the first principle axis (see S2 Table) the strongest negative contributions come from genes
involved in pancreatic development (e.g. ONECUT1, PDX1, SOX9, FOXA2,. . .). The strongest
positive contributions, however, do not come from a set of genes with as coherent a functional
annotation as the negatives except with regard to insulin trafficking and secretion; BACE2 and
PIM-3, which is also known to promote human pancreatic cancer growth [15].
For the second principle axis (see S3 Table) the strongest negative contributions come from
developmental genes for of a large number of tissue types and organ systems. The strongest
positive contributions come from transmembrane receptor protein kinases. The most notable
contribution comes from MST1R which has been implicated in KRAS oncogene activation in
PDAC [16].
Given the separation among tumor samples based on methylation of genes important for
development, we moved to examine whether there might be a correlation between methylation
of these genes and the disease-specific survival of the patients.
Definition of Survival+ and Survival- terms for methylation sites
We observed that methylation sites with positive or negative Cox regression scores formed two
groups with distinct properties, as discussed below. To simplify the conceptualization and
referencing of these two groups, we defined them as “survival-”or “survival+”, both significant-
ly correlated with increased methylation. For survival-, increased methylation was associated
with shorter survival times. Conversely, for survival+ increased methylation was associated
with longer survival times. Based on our filtering criteria and applying a p 0.05 threshold for
significance, we obtained a set of 17,251 survival+ sites and 3256 survival- sites.
Individual CpG site methylation correlates with patient survival
We tested whether other clinical variables known to affect DNAmethylation might account for
the correlations we observe. We performed the same Cox regression with censoring for each
site’s methylation against both patient age and tumor content (cellularity). We then took the Cox
scores based on survival and those based on each of the other variables and calculated the Pear-
son correlation of the two coefficients among all the sites in each of the survival+ and survival-
sites. For tumor quality, the correlation was 0.06 and for age, it was 0.08. Use of just the sites of
interest to this study (those with p-value< 0.05 in the survival and methylation comparison)
yielded correlations of 0.16 for age and -0.12 for tumor quality. Moreover the numbers of sites
where correlation was statistically significant for both methylation and age or methylation and
tumor content were quite small (n ~ 10). We therefore conclude that correlations between meth-
ylation levels and survival times are not significantly affected by patient age or tumor content.
Functional analysis reveals keys genes in pancreatic cell fate
commitment
Using the survival+ and survival- methylation sites individually and the entire ~250K methyla-
tion sites as background, we used the GREAT tool to search for significant associations with
DNAMethylation and Pancreatic Cancer
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various functional categories and pathways [17]. A subset of the significant associations found
by these queries are listed in Table 2 for the survival- sites and Table 3 for the survival+ sites.
For the survival- set of methylation sites, we observed a number of significant associations
with developmental processes and pathways specific to the pancreas, including key genes in-
volved in transcriptional regulation determining cellular differentiation in the pancreas. Links
were also noted between genes and processes of neural cell differentiation, a finding noted pre-
viously in a both an exome sequencing effort [5] and a DNA methylation study of PDAC [13].
Fig 2 is a schematic of cell lineages in the pancreas adapted from Zaret, et al. [18]. Genes
highlighted in red were enriched in the survival- set, including HHEX, ONECUT1, ISL1,
NKX2-2, and PAX6. HHEX, a homeobox gene, is critical for pancreatic development and
ONECUT1 is necessary for the timely expression of PDX1 and NEUROG3 in both dorsal and
pancreatic endoderm [19, 20]. NKX2-2 is required for pancreatic beta cell development [21],
ISL1 is required for islet cell development [22], and, PAX6 is required for the differentiation of
alpha cells [22].
It has been previously reported that the hypermethylation of ISL1 correlates with decreased
gene expression and aggressive progression of invasive bladder cancer [23]. The methylation of
NKX2-2 was identified as part of a signature for glioblastoma multiforme [24]. Finally, the
hypermethylation of PAX6 was observed to correlate with poor clinical outcome in gastric can-
cer [25, 26], development of non-small cell lung cancer [27] and transcriptional deactivation in
invasive ductal breast carcinoma [28, 29].
Survival- and survival+ have distinct positional propensities
Fig 3A plots the log-odds ratios for survival- and survival+ sites at various distances from the
transcription start sites of their nearest genes. The survival- sites, which have the clearest an-
notation results, were substantially enriched in the promoter regions of genes. In contrast, the
survival+ methylation sites, which, as a group, have less coherent association with particular
functional annotations were distributed more broadly and distal to the genes’ transcriptional
start sites. Similarly, the two categories of methylation sites have distinct statistical properties.
Fig 3B is a histogram of average methylation values for methylation sites of both categories.
Survival- and survival+ sites appear to have nearly separate and distinct distributions of meth-
ylation values. While survival- sites tend to have low methylation that increases with short-
ened survival times, the survival+ category is overwhelmingly comprised of CpG sites that are
hyper-methylated. We note that these two distributions reflect the background distribution of
all sites (see S1 Fig). The abundance of survival+ sites relative to survival- sites reflects the
larger background distribution of hypermethylated CpGs. As hypomethylated regions of the
genomes are typically associated with transcriptional start sites, it is likely that the survival-
sites are more directly related to transcriptional changes than the survival+ sites, which
are often in distal intergenic regions, and have a less clear relationship to transcriptional
regulation.
Toward Biomarker Development
Specific examples of the correlation between methylation and patient survival are presented in
Fig 4. Fig 4A displays three genes (FAM150A, ONECUT1, and RASSF10) that were locally en-
riched for survival- sites. The panel shows the chromosomal location, the structure, and a mag-
nified view of the DNA methylation tracks for the 11 PDAC patients with their survival time in
months listed on the left of the track as well as tracks for 2 pancreatitis and 3 normal samples.
The lowest portion of the Fig 4A panel depicts tracks for transcription factor binding regions
obtained from the ENCODE project [30]. Fig 4B depicts Kaplan-Meier curves for three specific
DNAMethylation and Pancreatic Cancer
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Table 2. Significant function and pathway associations for survival- sites.
FDR Q-
value
Enrichment Number of
Genes
GO Biological Process
regulation of transcription, DNA-dependent 8.13E-63 1.7 347
cell differentiation 7.36E-54 1.7 300
positive regulation of transcription from RNA polymerase II promoter 7.03E-43 2.2 96
neuron differentiation 1.78E-38 2 135
cell migration 2.31E-29 2.1 71
cell projection morphogenesis 3.08E-29 2.1 86
mesenchymal cell development 9.08E-28 3.5 23
neural crest cell migration 1.54E-23 4.8 12
axonogenesis 1.51E-21 1.9 81
Wnt receptor signaling pathway, calcium modulating pathway 3.92E-18 8.9 6
pancreas development 5.93E-17 2.6 16
chromatin assembly 5.52E-16 4.3 10
axon guidance 1.65E-15 1.9 60
type B pancreatic cell development 4.08E-15 8.7 2
negative regulation of synapse assembly 2.17E-12 10.2 2
neuron fate commitment 2.24E-12 2.4 22
negative regulation of transforming growth factor beta receptor signaling pathway 2.98E-12 3.4 6
epithelial to mesenchymal transition 3.11E-11 3.2 11
regulation of programmed cell death 5.23E-11 1.5 104
type B pancreatic cell differentiation 1.45E-10 5.5 2
regulation of angiogenesis 7.93E-09 2.5 15
neural precursor cell proliferation 8.86E-09 2.9 10
regulation of cell migration involved in sprouting angiogenesis 1.26E-07 7.6 2
Pathway Commons
Regulation of gene expression in early pancreatic precursor cells 2.48E-12 6.2 1
FOXM1 transcription factor network 3.45E-10 4.5 3
Regulation of beta-cell development 5.94E-10 2.7 9
Synthesis, Secretion, and Inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) 1.32E-08 5.7 2
Neurofascin interactions 3.33E-08 9.2 3
Signaling events mediated by HDAC Class III 9.27E-07 4.3 5
Class B/2 (Secretin family receptors) 9.39E-07 2.9 8
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a
nascent protein
1.05E-06 5.2 3
Noncanonical Wnt signaling pathway 1.39E-06 2 21
Post-chaperonin tubulin folding pathway 1.35E-06 5.8 2
Syndecan-4-mediated signaling events 1.16E-05 1.9 23
Incretin Synthesis, Secretion, and Inactivation 2.81E-04 2.8 5
Interleukin-1 signaling 3.57E-04 3.2 4
Serotonin receptors 3.62E-04 6.3 3
Validated targets of C-MYC transcriptional repression 6.05E-04 2.5 8
Transcription Factor Targets
Targets of Oct4, identified by ChIP-chip in embryonic stem cells 2.15E-15 2.4 26
Targets of Sox2, identified by ChIP-chip in embryonic stem cells 1.47E-15 2 45
Targets of Nanog, identified by ChIP-chip in embryonic stem cells 1.09E-10 1.7 57
Targets of CREB, identified by ChIP-chip in HEK293T cells in three different time points after forskolin
stimulation
3.40E-05 1.3 100
doi:10.1371/journal.pone.0128814.t002
DNAMethylation and Pancreatic Cancer
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Table 3. Significant function and pathway associations for survival+ sites.
FDR Q-value Enrichment Number of Genes
GO Biological Process
detection of chemical stimulus involved in sensory perception 4.2E-04 1.7 54
nucleotide-binding oligomerization domain containing 2 signaling pathway 5.1E-04 6.2 3
sensory perception of smell 9.8E-04 1.5 59
NF-kappaB binding 5.8E-04 2.3 12
olfactory receptor activity 6.1E-04 1.7 46
PANTHER Pathway
p53 pathway feedback loops 2 7.4E-04 1.8 24
doi:10.1371/journal.pone.0128814.t003
Fig 2. Schematic of cell lineage relationships in the pancreas.Genes that are well-established as playing key roles in cell fate are listed by name. Names
highlighted in red are genes enriched for survival-methylation sites.
doi:10.1371/journal.pone.0128814.g002
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Fig 3. (A) Enrichment (log-odds ratio) of survival+ and survival- sites in different distance bins relative to the
transcriptional start sites (TSS) of their nearest genes. (B) Histogram of average methylation scores for CpG
sites categorized as survival- and survival+.
doi:10.1371/journal.pone.0128814.g003
DNAMethylation and Pancreatic Cancer
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Fig 4. Genome browser visualization of DNAmethylation, patient survival, and gene structure. (A) Three genes where increased methylation in the
promoter region strongly correlates with decreased patient survival. Also shown are tracks corresponding to transcription factor binding evidence. (B)
Kaplan-Meier curves for one site from each gene occurring within a transcription factor binding site.
doi:10.1371/journal.pone.0128814.g004
DNAMethylation and Pancreatic Cancer
PLOS ONE | DOI:10.1371/journal.pone.0128814 June 3, 2015 9 / 18
sites—each taken from the gene immediately above it. A complimentary set of examples using
survival+ sites is provided in S2 Fig.
Comparison to known PDAC-associated genes
Employing a gene-centric approach, we counted the number of significant methylation sites
(survival+ or survival-) occurring in a given gene plus a 5 kilobase extension upstream of the
transcription start site. We then sorted these two lists and examined the top 10 entries in each.
The complete lists of genes and the number of significant methylation sites for each are given
in S4 Table.
Additionally, we looked at overlap between our gene sets and sets of genes with mutations
uncovered in two extensive sequencing studies of pancreatic cancers [4, 5]. For our gene lists,
we took only those that had 10 or more significant methylation sites (to reduce the false dis-
covery rate of any single site). This gave us 32 genes for the survival- set and 54 genes for the
survival+ set. Only one (COL5A1) appeared in both a list of mutated genes [4] and the sur-
vival+ list, while no overlap was noted with the survival- set. This lack of overlap between
genes enriched for survival- and survival+ methylation sites and genes associated with pan-
creatic cancer mutants is explained by two factors. The first is that we applied stringent crite-
ria for genes to be considered in order to minimize false discovery, and therefore we have
not necessarily captured all epigenetic changes. The second, and probably more important
observation, is that PDAC-associated mutant genes are not enriched for pancreatic de-
velopmental genes, but rather for signaling pathways. Thus mutations to these signaling
pathways likely confer survival benefits for the tumors, while developmental changes that
confer survival benefits are more efficiently modulated though epigenetic rather than genetic
changes.
Discussion
Genomic alterations and gene expression changes associated with pancreatic cancer have been
studied intensively, and a number of critical genes have been identified [4, 31, 32]. Quantitative
integration of multiple data-sources for genomic alterations, gene expression, and epigenetic
regulation with patient survival has aided in characterizing the relationships between the PI3K/
AKT and SRC pathways [10] and PDAC progression. In contrast to previous studies, we have
adopted the survival-based approach with a focus on potential epigenetic regulation via
DNAmethylation.
We found that the methylation of CpG sites correlated with patient survival in ~20,000 in-
stances out of ~250,000 measured. These sites fell into two categories we called survival- and
survival+ representing the relationship of increased methylation to survival. We also found
that these two types of sites had distinct positional propensities relative to the transcriptional
start sites of genes. While the survival- sites clustered near the TSS—corresponding to hyper-
methylation of promoter regions, the survival+ sites were more broadly distributed intrageni-
cally. As a result of this partitioning, and the generally more fully understood and
characterized promoter regions of genes, the survival- sites yielded clearer recovery of function-
al annotation and genes in the aggregate.
While the vast majority of DNA methylation studies have focused on the methylation status
of promoters and CpG islands, there is growing evidence that intronic methylation and/or
methylation sites that are not part of CpG islands also play a role in modulating gene expres-
sion [33, 34]. It is thought that these methylation of these intra-genic sites affects the role of en-
hancers of transcription [35–37]. Our study lends credence to this as the bulk of significant
methylation changes we observed were in the survival+ category (not proximal to the TSS).
DNAMethylation and Pancreatic Cancer
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The gene FAM150A had the greatest number of survival- sites. While not well-characterized
in the literature, in a recent study of renal cell carcinomas, it was found to be hypermethylated
in the cluster of patients with aggressive cancer and poor survival [38, 39]. The role of ONE-
CUT1 (HNF6) in pancreatic development is well established. In particular, it is thought to act
as a phenotypic switch in acinar-to-ductal metaplasia that can lead to pancreatic intraepithelial
neoplasia and subsequent PDAC [40]. Studies in mouse indicate ONECUT1 has tumor sup-
pressor activity [41]. Another well-known tumor suppressor in our top 10 list is RASSF10. Re-
cent studies have identified it as epigenetically silenced via promoter hypermethylation in a
number of cancers [42–52]. RNF207 was also recently identified as a tumor suppressor in neu-
roblastomas [53]. PCDH9 is frequently lost in hepatocellular carcinomas, its down-regulation
is associated with tumor cell migration, and PCDH9-negative tumors correlate with signifi-
cantly shorter survival times for glioma patients [54, 55]. Likewise, the loss of one allele of
BRF1 is associated with a variety of different tumors [56]. As a subunit of TFIIB, the deregula-
tion of this gene likely contributes to the deregulation of RNA pol III transcription widely ob-
served in cancer cells [57].
Of the top 10 survival- genes, only three (MAP6, RIN3, and HIST1H2BI) lacked clear-cut
evidence of an oncogenic or tumor suppressor role in the literature. RIN3 is a negative regula-
tor of mast cell response to stem cell factor [58], and may play a suppressive role in tumor inva-
siveness. HIST1H2BI does not appear to have a known role in cancer aside from a general
chromatin structural role.
The remaining gene in our top 10 list encodes an miRNA (MIR96) known to suppress
KRAS and function as a tumor suppressor in pancreatic cancer [59]. As a result, we also exam-
ined other miRNAs appearing in our survival- gene list. Though not in the top 10, we found
two more miRNA genes with more than 5 significant methylation sites. MIR130B is down-reg-
ulated in pancreatic cancer tissues and its expression is a useful prognostic for pancreatic can-
cer patients [60]. MIR196A1 has also been identified as having aberrant expression associated
with abnormal apoptosis, invasion and proliferation of pancreatic cancer cells [61].
Examining the 10 genes with the most numerous survival+ sites yielded the following find-
ings. PTPRN2 is a well-known member of the major auto-antigens in insulin-dependent diabe-
tes mellitus. It has also been identified as a hypermethylated biomarker in squamous cell lung
cancer [62]. CDH4 is aberrantly methylated in its promoter region in gastric and colorectal
cancer and may act as an epigenetically silenced tumor suppressor in nasopharyngeal carcino-
ma [63, 64]. MAD1L1 is a well-studied cell cycle checkpoint gene with mutations implicated in
multiple types of cancer [65]. CBFA2T3 is found in pediatric acute myeloid leukemia and is in-
volved in chromosomal translocations and fusion protein products (CBFA2T3-GLIS2) [66].
Aberrant methylation of CBFA2T3 promoter has been found in breast cancer tissue compared
to normal [67]. CBFA2T3 is also found in IGH chromosomal translocations in pediatric B-cell
lymphoma [68]. The collagen-remodeling gene, COL5A1, was used in a 10-gene expression
signature associated with poor patient survival in high-grade serous ovarian cancer and its ex-
pression appears to promote metastasis [69]. CAMTA1 is a tumor suppressor candidate found
to inhibit growth in neuroblastomas and appears to play a role in the development of glioma
stem cells [53, 70–72]. The H3K9me1 methyltransferase PRDM16 helps protect genomic integ-
rity [73]. Translocations of this gene are found in acute myeloid leukemia and myelodysplastic
syndrome and correlated with poor patient survival [74]. SHANK2 has been suggested as a
novel oncogene as its over-expression in esophageal squamous cell carcinoma is associated
with cell proliferation and protection against cell death [75].
For two of the top 10 genes there was little literature annotation. High levels of the RBFOX4
protein have been found in supratentorial ependymomas.[76], while there is essentially no link
in the literature to a cancer association for TRAPPC9.
DNAMethylation and Pancreatic Cancer
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As we found interesting miRNAs in our set of survival- genes, we looked for them in the sur-
vival+ set, as well. Despite the larger numbers of survival+ sites relative to survival site, there
were no miRNA genes associated with more than 5 of this class of sites.
Following a closer inspection of individual genes associated with multiple occurrences of
survival+ and survival- sites, we found that nearly all had been identified via other studies with
other types of data as playing a role in cancer, even if they have not been investigated specifical-
ly in relation to PDAC. Our findings are consistent with previous studies reporting correlations
between promoter hypermethylation or transcription inactivation for several key developmen-
tal regulatory genes or genes with tumor suppressive capacity in other cancers. The pathways
that are enriched for survival-related epigenetic changes correspond to some of the pathways
previously identified in a broad sense. The appearance of 3 miRNA genes in our survival- set,
all of which have been identified as key transcription regulators in PDAC, is of particulate note
and gives us greater confidence in the approach we have taken.
Finally, as a preliminary test of the potential predictive utility of DNAmethylation for pan-
creatic cancer patient survival, we tested 3 survival- sites occurring in 3 genes with multiple sur-
vival- sites at locations for which there is evidence of protein binding. The methylation values
at each of these sites could dichotomize the patients into short survival and longer survival
with statistical significance.
The results of this approach show clearly that DNA methylation changes of key cell fate de-
termining genes is strongly associated with PDAC progression. This study should motivate col-
lection of more sample data to confirm our results as well as to develop biomarkers based on
DNAmethylation changes associated with these key genes.
Methods and Materials
Patients and samples
All work was conducted with the approval of the University of California, Los Angeles (UCLA)
Institutional Review Board with written consent from all patients. Samples from PDAC tumors
and nonmalignant pancreas were snap frozen at the time of surgery. Tumor content was as-
sessed on hematoxylin and eosin sections by a practicing gastrointestinal pathologist (DWD).
All clinicopathologic and survival information for patients was extracted from a prospectively
maintained UCLA surgical database of pancreatic patients. Overall survival was determined by
searching the Social Security Death Index and survival intervals were calculated from date of
surgery to date of confirmed death or last patient contact.
For this study, a total of 16 samples were used, including 11 PDAC tumors, 2 normal sam-
ples and 3 chronic pancreatitis samples. Clinical details for these samples are given in S1 Table.
Reduced representation bisulfite sequencing
Genomic DNA from all samples was extracted to create libraries for reduced representation bi-
sulfite sequencing (RRBS) following a standard protocol [77]. Digests were performed with the
methylation-insensitive restriction enzyme, MspI, and fragments ranging from 50 to 300 bases
were selected to enrich for CpG rich regions. After digestion, samples were ligated with Illu-
mina adaptors, size selected, denatured and treated with sodium bisulfite to reveal their meth-
ylation state. Libraries were sequenced using Illumina Hiseq 2000 sequencers.
Sequencing reads were mapped to the human reference genome (hg19) using the BS Seeker2
set of computational tools [78]. As bisulfite treatment converts unmethylated cytosines to thy-
mines, we computed the methylation level at each genomics CpG site as the fraction of reads
uniquely mapped to that site containing a cytosine.
DNAMethylation and Pancreatic Cancer
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Data Filtering
We filtered the set of methylation sites for subsequent analysis using two statistical criteria in-
tended to select biologically relevant sites and improve the quality of downstream calculations.
First, as the methylation state at a given site is a binomial frequency estimate, we computed
confidence intervals using the Clopper-Pearson method [79]. We included only sites where
methylation frequencies for each of the 16 samples had 95% confidence intervals less than 0.25.
Second, we computed the standard deviation across the 16 samples and culled sites with a stan-
dard deviation< = 0.05 for further analysis.
Statistical Analysis
Principal Component Analysis [80] was performed on methylation vectors comprised of all
sites that passed the filters described above. Cox regression [81] with censoring was used to cal-
culate a regression coefficient and associated p-value at each site individually to determine the
sign and strength of relationship with the survival data. Likewise, for some sites of interest pre-
sented in Results and Discussion, we computed Kaplan-Meier [82] curves and log-rank p-val-
ues by dichotomizing the samples based on the average methylation value at each site.
Function and Pathway Analysis
To investigate the functional implications of methylation sites with strong correlation to sur-
vival, we utilized the Genomic Regions Enrichment of Annotations Tool (GREAT) [17]. This
tool aggregates multiple databases of biomolecular annotation and computes statistical associa-
tions between these annotations and a given input set of genomic regions. For our input, we
used the subset of methylation sites with p-values less than 0.05. For the background, we used
all sites that passed the two quality filters. For the GREAT input parameters we chose the single
nearest gene option and a maximal extension of 100 kilobases from the transcription start site
of each gene.
Given the large number of CpG sites examined in this study, we attempted to apply stan-
dard multiple-testing corrections [83] to these p-values. As a result of the under-representation
of low p-values in our data compared to uniform random expectation, the false discovery rates
we obtained was likely inflated. However, as shown in Results and Discussion, using uncorrect-
ed p-values for selecting loci in an aggregate manner (per gene or genomic region) provided
convincing recovery of functional annotation and genes previously highlighted in the literature,
suggesting our approach is robust. Finally, we compared the set of genes most strongly en-
riched with significant methylation sites to the lists of genes found to be significantly mutated
in extensive exome sequencing project [4, 5].
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